Literature DB >> 21841617

Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

J M Lestner1, R Baburaj, C M B Edwards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21841617     DOI： 10.12968/hmed.2011.72.7.412

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


× No keyword cloud information.
  4 in total

1.  Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

Authors:  Edwin K Jackson; Stanton J Kochanek; Delbert G Gillespie
Journal:  Hypertension       Date:  2012-07-16       Impact factor: 10.190

Review 2.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 3.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

4.  Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.

Authors:  Dongmei Cheng; Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.